Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...

The drugmaker is already carrying out a second phase 3 trial of Fasenra in CRSwNP – called ORCHID – which isn't due to generate results until September 2023, according the listing for the ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

GlaxoSmithKline ( (GSK)) has provided an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly ...